

BETH C. DRAIN, CA CSR NO. 7152

BEFORE THE
APPLICATION REVIEW SUBCOMMITTEE OF THE
INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE
TO THE
CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE
ORGANIZED PURSUANT TO THE
CALIFORNIA STEM CELL RESEARCH AND CURES ACT
REGULAR MEETING

LOCATION: VIA ZOOM

DATE: MAY 29, 2025
9 A.M.

REPORTER: BETH C. DRAIN, CA CSR
CSR. NO. 7152

FILE NO.: 2025-13

BETH C. DRAIN, CA CSR NO. 7152

I N D E X

ITEM DESCRIPTION	PAGE NO.
------------------	----------

OPEN SESSION

1. CALL TO ORDER	3
------------------	---

2. ROLL CALL	3
--------------	---

3. CONSIDERATION OF AN APPLICATION SUBMITTED IN RESPONSE TO CLINICAL TRIAL STAGE PROJECTS PROGRAM ANNOUNCEMENTS (CLIN 1, 2, OR 4)	4
--	---

CLOSED SESSION	NONE
-----------------------	-------------

4. DISCUSSION OF CONFIDENTIAL INTELLECTUAL PROPERTY OR WORK PRODUCT, PREPUBLICATION DATA, FINANCIAL INFORMATION, CONFIDENTIAL SCIENTIFIC RESEARCH OR DATA, AND OTHER PROPRIETARY INFORMATION RELATING TO APPLICATIONS SUBMITTED IN RESPONSE TO AGENDA ITEM 3 ABOVE. (HEALTH & SAFETY CODE 125290.30(F) (3) (B) AND (C)).

OPEN SESSION

5. GENERAL COMMENTS ON ARS PROCESS	NONE
------------------------------------	------

6. PUBLIC COMMENT	NONE
-------------------	------

7. ADJOURNMENT	15
----------------	----

BETH C. DRAIN, CA CSR NO. 7152

MAY 29, 2025; 9 A.M.

CHAIRMAN IMBASCIANI: OKAY. GOING TO CALL
TO ORDER THIS MEETING OF THE APPLICATION REVIEW
SUBCOMMITTEE. THANK YOU ALL FOR ATTENDING ON THIS
BEAUTIFUL THURSDAY MORNING. SCOTT, WE CAN START
WITH A ROLL CALL.

MR. TOCHER: CERTAINLY. DAN BERNAL.

MR. BERNAL: PRESENT.

MR. TOCHER: MARIA BONNEVILLE.

VICE CHAIR BONNEVILLE: PRESENT.

MR. TOCHER: JUDY CHOU. LEONDRA
CLARK-HARVEY.

DR. CLARK-HARVEY: PRESENT.

MR. TOCHER: ANNE-MARIE DULIEGE. YSABEL
DURON.

MS. DURON: HERE.

MR. TOCHER: MARK FISCHER-COLBRIE.

DR. FISCHER-COLBRIE: HERE.

MR. TOCHER: ELENA FLOWERS.

DR. FLOWERS: PRESENT.

MR. TOCHER: DAVID HIGGINS.

DR. HIGGINS: HERE.

MR. TOCHER: VITO IMBASCIANI.

CHAIRMAN IMBASCIANI: HERE.

BETH C. DRAIN, CA CSR NO. 7152

1 MR. TOCHER: RICH LAJARA.
2 MR. LAJARA: PRESENT.
3 MR. TOCHER: CHRISTINE MIASKOWSKI.
4 DR. MIASKOWSKI: PRESENT.
5 MR. TOCHER: ADRIANA PADILLA.
6 DR. PADILLA: HERE.
7 MR. TOCHER: JOE PANETTA.
8 MR. PANETTA: HERE.
9 MR. TOCHER: MARVIN SOUTHARD.
10 DR. SOUTHARD: HERE.
11 MR. TOCHER: KAROL WATSON. Yael WYTE.
12 DR. WYTE: HERE.
13 MR. TOCHER: KEVIN XU.
14 DR. DULIEGE: SCOTT, THIS IS ANNE-MARIE
15 AND I'M HERE.
16 MR. TOCHER: GREAT. THANK YOU,
17 ANNE-MARIE. EXCELLENT. WE HAVE A QUORUM OF 15
18 MEMBERS.
19 CHAIRMAN-IMBASCIANI: BEAUTIFUL. THANK
20 YOU VERY MUCH. WE'RE GOING TO CONSIDER AN
21 APPLICATION SUBMITTED IN RESPONSE TO OUR CLINICAL
22 TRIAL STAGE PROJECTS PROGRAM ANNOUNCEMENT. AND I AM
23 GOING TO PASS THE MICROPHONE, SO TO SPEAK, OVER TO
24 DR. HAYLEY LAM FOR THE PRESENTATION. THANK YOU,
25 HAYLEY.

BETH C. DRAIN, CA CSR NO. 7152

1 DR. LAM: THANK YOU, CHAIR IMBASCIANI.
2 GIVE ME A MOMENT HERE TO SHARE MY SLIDES. ALL
3 RIGHT. CAN FOLKS SEE THAT? THANK YOU.

4 SO MY PLEASURE THIS MORNING TO PRESENT THE
5 GRANTS WORKING GROUP RECOMMENDATIONS FOR THE
6 CLINICAL PROGRAM. AS ALWAYS, WE BEGIN WITH OUR
7 MISSION: ACCELERATING WORLD-CLASS SCIENCE TO
8 DELIVER TRANSFORMATIVE REGENERATIVE MEDICINE
9 TREATMENTS IN AN EQUITABLE MANNER TO A DIVERSE
10 CALIFORNIA AND WORLD.

11 THE CURRENT CLINICAL BUDGET STATUS IS AS
12 FOLLOWS. THERE WAS 76.7 MILLION APPROVED BY THE
13 BOARD FOR THE REMAINDER OF THE FISCAL YEAR. AS OF
14 RIGHT NOW, 58.4 HAS BEEN APPROVED BY THIS GROUP.
15 AND TODAY WE HAVE 4.7 MILLION REQUESTED, AND THAT
16 WOULD LEAVE ABOUT JUST UNDER 14 MILLION REMAINING IF
17 APPROVED.

18 THE CLINICAL SCORING SYSTEM IS A SYSTEM OF
19 1-2-3. AND 1 IS A RECOMMENDATION FOR FUNDING. A 2
20 IS A NOT FUND AT THIS TIME, BUT INVITES THE
21 APPLICANT TO RESUBMIT WITH FIXABLE CHANGES. AND 3
22 IS DO NOT RECOMMEND FOR FUNDING AND THE PROJECT
23 CANNOT RETURN FOR A FEW MONTHS.

24 THE SCIENTIFIC MEMBERS OF THE WORKING
25 GROUP SCORE HOLISTICALLY A 1-2-3 BASED ON THE

BETH C. DRAIN, CA CSR NO. 7152

1 SCIENTIFIC REVIEW CRITERIA WHICH ARE AS FOLLOWS. SO
2 DOES THE PROJECT HOLD THE NECESSARY SIGNIFICANCE AND
3 POTENTIAL IMPACT? SO DOES IT HAVE OVERALL VALUE?
4 IS IT WORTH PROCEEDING? SECONDLY, IS THE RATIONALE
5 SOUND? SO DOES THE BODY OF DATA THAT THEY HAVE
6 GATHERED SUPPORT MOVING FORWARD? IS THE PROJECT
7 WELL-PLANNED AND DESIGNED? SO ARE THE ACTIVITIES
8 AND THINGS THAT THEY PLAN TO DO WITH CIRM FUNDING
9 APPROPRIATE FOR THE GOAL OF THE PROJECT? AND IS THE
10 PROJECT FEASIBLE? SO DO THEY HAVE THE PEOPLE, TEAM,
11 LEADERSHIP, AND CONTRACTORS, AND ALL THE RESOURCES
12 IN PLACE TO EXECUTE THE PROJECT IN A TIMELY WAY?

13 THE REVIEW PANEL IS COMPOSED OF THREE
14 DIFFERENT TYPES OF FOLKS. SO WE HAVE UP TO 15
15 SCIENTIFIC GRANTS WORKING GROUP MEMBERS THAT PROVIDE
16 A SCIENTIFIC EVALUATION OF THE DISEASE AREA,
17 REGULATORY, MANUFACTURING, PRODUCT DEVELOPMENT.
18 THEY PROVIDE A SCIENTIFIC SCORE ON ALL THE
19 APPLICATIONS. WE HAVE OUR GRANTS WORKING GROUP
20 BOARD MEMBERS WHO SUGGEST A SCIENTIFIC SCORE AND
21 PROVIDE A PATIENT PERSPECTIVE ON THE POTENTIAL
22 IMPACT OF THE PROJECT. AND WE ALSO HAVE OUR AD HOC
23 SPECIALISTS THAT PROVIDE EXPERTISE THAT MAY NOT BE
24 COVERED BY THE STANDING PANEL, AND THEY PROVIDE
25 INITIAL, BUT NOT A FINAL SCIENTIFIC SCORE.

1 SO WITH THAT, I WILL -- THIS DOESN'T
2 INCLUDE -- SORRY. THERE IS ONE CONFLICT ON THE
3 GROUP TODAY, BUT I THINK YOU KNOW WHO YOU ARE.

4 SO ON STRAIGHT TO THE APPLICATION. SO FOR
5 YOUR CONSIDERATION TODAY IS CLIN1-17090, DEVELOPMENT
6 OF A NOVEL INTRAVITREAL AAV GENE THERAPY FOR THE
7 RARE DISEASE BLUE CONE MONOCHROMACY. THIS IS A GENE
8 THERAPY FOR THE INDICATION. AND THE APPLICANT IS
9 SEEKING FUNDING FOR IND APPROVAL IN THE AMOUNT OF
10 4.691 MILLION. AND THE APPLICANT DOES NOT HAVE
11 REQUIRED CO-FUNDING AND IS A CALIFORNIA
12 ORGANIZATION.

13 A LITTLE BIT OF BACKGROUND ABOUT THE
14 PROJECT. SO THIS IS A RARE, INHERITED DISEASE
15 ESSENTIALLY WHERE THERE ARE MUTATIONS IN THE
16 FUNCTION IN THE RED AND GREEN PHOTORECEPTORS IN THE
17 RETINA. AND SO THIS IS USUALLY DIAGNOSED IN INFANCY
18 AND IMPACTS THE QUALITY OF LIFE OF PEOPLE WITH THIS
19 CONDITION CAUSING LOW VISION, PHOTSENSITIVITY. SO
20 SENSITIVITY TO LIGHT AND IMPAIRED COLOR
21 DISCRIMINATION AND, OF COURSE, ALSO SOME
22 UNCONTROLLED EYE MOVEMENT IS POSSIBLE AS WELL.

23 THE CURRENT TREATMENTS ARE SYMPTOMATIC
24 ONLY. SO SORT OF VISION AIDS AND SUNGLASSES, THAT
25 SORT OF THING. THE PROPOSED THERAPY IS DESIGNED AS

1 A ONE-TIME INJECTION INTO THE EYE AND AIMS TO
2 ESSENTIALLY EXPRESS A FUNCTIONAL COPY OF THE L-OPSIN
3 GENE IN THE PHOTORECEPTORS AND HOPEFULLY RESTORE
4 VISUAL FUNCTION. SO THIS WOULD BE A FUNCTIONAL
5 IMPROVEMENT ESSENTIALLY FOR THE PATIENTS THAT HAVE
6 THIS DISEASE AS OPPOSED TO MANAGING SYMPTOMS ONLY.
7 AND THE RELEVANCE TO CIRM IS THIS IS A GENE THERAPY
8 PRODUCT.

9 CIRM DOES NOT CURRENTLY HAVE ANY
10 TRANSLATIONAL OR CLINICAL AWARDS ADDRESSING THIS
11 INDICATION. AND THE APPLICANT HAS NOT RECEIVED
12 PRIOR CIRM FUNDING.

13 SO IN SUMMARY FOR CONSIDERATION TODAY IS
14 CLIN1-17090. THIS APPLICATION RECEIVED A UNANIMOUS
15 RECOMMENDATION FOR FUNDING WITH 15 VOTES TO A SCORE
16 OF 1 FROM THE SCIENTIFIC MEMBERS OF THE GRANTS
17 WORKING GROUP, AND THE CIRM TEAM CONCURS WITH THIS
18 RECOMMENDATION TO FUND THE APPLICATION FOR THE
19 AMOUNT LISTED HERE, JUST UNDER 4.7 MILLION.

20 AND I WILL HAND IT BACK TO CHAIR
21 IMBASCIANI FOR DISCUSSION.

22 CHAIRMAN IMBASCIANI: THANK YOU, HAYLEY.

23 I'M GOING TO OPEN THE DISCUSSION ON THIS
24 GRANT APPLICATION TO BOARD MEMBERS. STARTING OFF
25 THE DISCUSSION, I'M VERY HAPPY. I KNOW OUR

BETH C. DRAIN, CA CSR NO. 7152

1 PORTFOLIO IS VERY RICH WITH OTHER DISEASES THAT
2 AFFECT THE RETINA OR THE CORNEA, OTHER PARTS OF THE
3 EYE. HAYLEY MENTIONS THAT THIS IS THE FIRST TIME
4 THAT WE HAVE CONSIDERED FUNDING SOMETHING THAT LOOKS
5 AT RODS AND CONES THAT CAUSE VISUAL IMPAIRMENT. SO
6 I'M VERY HAPPY TO SEE THAT, EVEN THOUGH OUR
7 PORTFOLIO IS RICH IN EYE-RELATED DISEASES, THAT WE
8 CONTINUE TO EXPAND THE UNMET NEED.

9 SO ANY OTHER BOARD MEMBERS WANT TO MAKE
10 COMMENTS ON THE APPLICATION? CAN WE START WITH A
11 MOTION? THE CHAIR WILL ENTERTAIN TO ACCEPT THE
12 RECOMMENDATION OF THE WORKING GROUP.

13 DR. SOUTHARD: SO MOVED.

14 CHAIRMAN IMBASCIANI: MARVIN. THANK YOU.

15 MS. DURON: SECOND.

16 MR. TOCHER: AND THE SECOND IS BY YSABEL
17 DURON.

18 CHAIRMAN IMBASCIANI: THANK YOU, YSABEL.
19 OKAY. FLOOR IS OPEN TO DISCUSSION. JOE PANETTA.

20 MR. PANETTA: THANKS, VITO. I CAN'T FIND
21 MY LITTLE HAND RAISE HERE.

22 HAYLEY, THANKS AS USUAL FOR A FANTASTIC
23 PRESENTATION.

24 JUST A COMMENT FIRST OF ALL, THAT THIS IS
25 ONE OF THOSE THINGS THAT I BELIEVE IS A THERAPY THAT

BETH C. DRAIN, CA CSR NO. 7152

1 IS A PERFECT OPPORTUNITY, HOPEFULLY, FOR CIRM TO
2 REALLY SHOW ITS VALUE IF THIS WORKS. IT'S A GENE
3 THERAPY. I KNOW WE'VE GOT A LOT OF VISION-RELATED
4 THERAPIES IN DEVELOPMENT, BUT THIS IS ONE OF THOSE
5 THINGS THAT STRIKES ME THAT IF THIS WORKS, IT'S A
6 REAL OPPORTUNITY TO SAY WE MADE AN IMPACT.

7 I'M ASSUMING THE PREVALENCE OF THIS IN THE
8 POPULATION IS NOT GREAT, BUT THAT WAS MY OTHER
9 QUESTION.

10 DR. LAM: PREVALENCE WORLDWIDE IS ONE IN A
11 100,000. AND THERE IS ESTIMATED ABOUT 3,000 FOLKS
12 IDENTIFIED WITH THIS IN THE UNITED STATES.

13 MR. PANETTA: THANKS.

14 CHAIRMAN IMBASCIANI: NO ONE WANTS TO
15 SPARE THE ROD TO SAVE THE CONE. WE CAN -- NO
16 FURTHER DISCUSSION FROM BOARD MEMBERS.

17 DR. LAM: THERE IS A HAND RAISED ON THE
18 PHONE.

19 MR. TOCHER: IT'S FOR PUBLIC COMMENT.

20 MS. MANDAC: THEY'RE PUBLIC COMMENT.

21 CHAIRMAN IMBASCIANI: I'M GOING TO SEGUE
22 TO PUBLIC COMMENT NOW. WILL THE INDIVIDUAL WHO'S
23 CALLING IN PLEASE IDENTIFY THEMSELVES. AND YOU HAVE
24 THREE MINUTES TO ADDRESS THE BOARD. THANK YOU.

25 MS. MANDAC: BEFORE YOU START, THERE IS

BETH C. DRAIN, CA CSR NO. 7152

1 GOING TO BE A TIMER. WE WILL MUTE YOU WHEN YOUR
2 TIME STARTS. WE'LL START WITH THE NUMBER ENDING IN
3 9994. YOUR TIME BEGINS NOW. PHONE NUMBER
4 281-302-9994, YOU HAVE THE FLOOR. YOU'LL NEED TO
5 UNMUTE.

6 MR. CAVITT: HELLO. MY NAME IS JOHN
7 CAVITT, AND I AM THE CO-FOUNDER OF BLUEGEN
8 THERAPEUTICS FOUNDATION AND FATHER OF THREE CHILDREN
9 WITH BCM. SO ON BEHALF OF OUR TEAM, THE MANY
10 SCIENTISTS WHO'VE WORKED TO GET HERE, AND THE
11 COUNTLESS FAMILIES THAT WILL BE IMPACTED BY THIS
12 POTENTIAL THERAPY. I WANT TO THANK YOU FOR ALL THE
13 DILIGENCE THAT WAS DONE ON THIS PROGRAM. SO THANK
14 YOU.

15 CHAIRMAN IMBASCIANI: IS THERE ANY OTHER
16 MEMBER OF THE PUBLIC WHO WANTS TO SPEAK?

17 MS. MANDAC: YES. WE DO HAVE TWO OTHER
18 MEMBERS OF THE PUBLIC WITH THEIR HANDS RAISED. THE
19 NEXT PHONE NUMBER WILL BE THE 212-920-9834. YOU
20 HAVE THE FLOOR. IF YOU COULD PLEASE UNMUTE.

21 DR. NAGIEL: HELLO. HELLO, EVERYONE. MY
22 NAME IS AARON NAGIEL. I'M THE PI ON THIS GRANT AND
23 THE CHIEF OF RETINA AT CHILDREN'S HOSPITAL LOS
24 ANGELES IN CALIFORNIA HERE. AND I WANT TO REALLY
25 THANK CIRM FOR THEIR ENTHUSIASTIC SUPPORT OF THIS

BETH C. DRAIN, CA CSR NO. 7152

1 WORK. AND I HOPE THAT THIS DECISION BY CIRM WILL
2 REPRESENT A HUGE MILESTONE FOR BCM PATIENTS AND
3 FAMILIES AND THE ENTIRE RETINAL DYSTROPHY COMMUNITY
4 AS WE MOVE THIS THERAPY FURTHER TOWARDS CLINICAL
5 TRIALS.

6 AS SOMEONE WHO IS DOING A LOT OF GENE
7 THERAPY WORK IN CALIFORNIA, BOTH FOR FDA APPROVED
8 (UNINTELLIGIBLE) AND OTHER TRIALS. I KNOW THAT THIS
9 WILL JUST BE ANOTHER WONDERFUL MILESTONE JUST MOVING
10 THE FIELD FORWARD AND PROUD TO HAVE A BASE IN
11 CALIFORNIA. SO THANK YOU ALL.

12 CHAIRMAN IMBASCIANI: THANK YOU. AND WE
13 HAVE ANOTHER MEMBER OF THE PUBLIC WISHING TO SPEAK.

14 MS. MANDAC: ONE MORE. PHONE NUMBER (617)
15 304-1691, IF YOU COULD PLEASE UNMUTE. SO CALLER
16 (617) 304-1691, YOU DO HAVE THE FLOOR.

17 DR. KISS: SORRY. THIS IS SZILARD KISS.
18 I'M HAVING TROUBLE UNMUTING. HOPEFULLY YOU CAN HEAR
19 ME. I'M A CO-FOUNDER OF BLUEGEN THERAPEUTICS. HAVE
20 BEEN IN THE GENE THERAPY SPACE FOR SOME TIME NOW.
21 AND I WANT TO THANK THE VOTERS OF CALIFORNIA AND THE
22 CIRM TEAM FOR SUPPORT OF THIS FIRST-IN-DISEASE
23 TREATMENT THAT CAN NOW MOVE CLOSER TO HELPING
24 PATIENTS WITH THIS DEVASTATING DISEASE. SO THANK
25 YOU SO MUCH.

BETH C. DRAIN, CA CSR NO. 7152

1 CHAIRMAN IMBASCIANI: THANK YOU FOR YOUR
2 COMMENT AND YOUR WORK. ANY OTHER MEMBERS,
3 CLAUDETTE?

4 MS. MANDAC: NO. THERE ARE NO MORE HANDS
5 RAISED.

6 CHAIRMAN IMBASCIANI: OKAY. THERE'S NO
7 MEMBER OF THE PUBLIC. ANY FINAL COMMENTS FROM BOARD
8 MEMBERS? IF NOT, SCOTT, I THINK WE CAN CALL THE
9 ROLL.

10 MR. TOCHER: THE MOTION IS TO FUND
11 APPLICATION CLIN1-17090.

12 DAN BERNAL.

13 MR. BERNAL: AYE.

14 MR. TOCHER: LEONDRA CLARK-HARVEY.

15 DR. CLARK-HARVEY: AYE.

16 MR. TOCHER: ANNE-MARIE DULIEGE.

17 DR. DULIEGE: AYE.

18 MR. TOCHER: YSABEL DURON.

19 MS. DURON: YES.

20 MR. TOCHER: MARK FISCHER-COLBRIE.

21 DR. FISCHER-COLBRIE: YES.

22 MR. TOCHER: ELENA FLOWERS.

23 DR. FLOWERS: YES.

24 MR. TOCHER: DAVID HIGGINS.

25 DR. HIGGINS: YES.

BETH C. DRAIN, CA CSR NO. 7152

1 MR. TOCHER: VITO IMBASCIANI.

2 CHAIRMAN IMBASCIANI: YES.

3 MR. TOCHER: RICH LAJARA.

4 MR. LAJARA: YES.

5 MR. TOCHER: CHRISTINE MIASKOWSKI.

6 DR. MIASKOWSKI: YES.

7 MR. TOCHER: ADRIANA PADILLA.

8 DR. PADILLA: YES.

9 MR. TOCHER: JOE PANETTA.

10 MR. PANETTA: YES.

11 MR. TOCHER: MARVIN SOUTHARD.

12 DR. SOUTHARD: YES.

13 MR. TOCHER: Yael WYTE.

14 DR. WYTE: YES.

15 MR. TOCHER: ARE THERE ANY BOARD MEMBERS
16 WHO JOINED THAT I HAVE NOT CALLED? NO. WELL, IN
17 THAT EVENT, THE MOTION CARRIES UNANIMOUSLY.

18 CHAIRMAN IMBASCIANI: WELL, THANK YOU VERY
19 MUCH. THANKS, SCOTT, FOR VOTE. THANK YOU, HAYLEY,
20 FOR THE PRESENTATION.

21 ARE THERE ANY COMMENTS FROM ANYONE ON THE
22 ARS PROCESS?

23 VICE CHAIR BONNEVILLE: VITO, I JUST
24 WANTED TO MAKE A COMMENT. THIS WAS OUR LAST CLIN
25 AWARD UNDER THE CURRENT PROGRAM ANNOUNCEMENT, AND

BETH C. DRAIN, CA CSR NO. 7152

1 EVERYTHING MOVING FORWARD WILL BE UNDER OUR NEW
2 STRATEGIC ALLOCATION FRAMEWORK. AND SO I THINK
3 THAT'S A REALLY EXCITING THING TO LOOK FORWARD TO.
4 SO THANKS TO THE TEAM.

5 CHAIRMAN IMBASCIANI: GREAT. THANK YOU,
6 MARIA. WE REACHED A MILESTONE.

7 NO COMMENTS ON THE PROCESS. ANY MEMBER OF
8 THE PUBLIC WANT TO SAY ANYTHING TO THE MEMBERS OF
9 THIS COMMITTEE, WHETHER IT'S ON THE AGENDA TODAY OR
10 NOT? AND I SEE NO HANDS UP.

11 OKAY. SO I WANT TO THANK THE MEMBERS OF
12 THE BOARD FOR PARTICIPATING IN THIS MEETING TODAY.
13 AND WE'RE GOING TO ADJOURN AND CONVENE AGAIN IN
14 SEPTEMBER. THERE IS NO ARS MEETING IN JUNE. OKAY.
15 THANK YOU.

16 (THE MEETING WAS THEN ADJOURNED AT 9:17 A.M.)
17
18
19
20
21
22
23
24
25

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE VIRTUAL PROCEEDINGS BEFORE THE APPLICATION REVIEW SUBCOMMITTEE OF THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD ON MAY 29, 2025, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CA CSR 7152
133 HENNA COURT
SANDPOINT, IDAHO
(208) 920-3543